vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $205.4M, roughly 1.0× COLLEGIUM PHARMACEUTICAL, INC). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 8.3%, a 49.1% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $122.4M).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
COLL vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $207.8M |
| Net Profit | $17.0M | $119.2M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | 52.2% |
| Net Margin | 8.3% | 57.4% |
| Revenue YoY | 12.9% | — |
| Net Profit YoY | 35.3% | 330.1% |
| EPS (diluted) | $0.48 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | — | ||
| Q3 25 | $209.4M | $207.8M | ||
| Q2 25 | $188.0M | — | ||
| Q1 25 | $177.8M | — | ||
| Q4 24 | $181.9M | — | ||
| Q3 24 | $159.3M | $0 | ||
| Q2 24 | $145.3M | $0 | ||
| Q1 24 | $144.9M | $0 |
| Q4 25 | $17.0M | — | ||
| Q3 25 | $31.5M | $119.2M | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $9.3M | $-51.8M | ||
| Q2 24 | $19.6M | $-52.8M | ||
| Q1 24 | $27.7M | $-39.6M |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | — | ||
| Q3 25 | 29.7% | 52.2% | ||
| Q2 25 | 18.7% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 21.9% | — | ||
| Q2 24 | 32.7% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | 8.3% | — | ||
| Q3 25 | 15.0% | 57.4% | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 13.5% | — | ||
| Q1 24 | 19.1% | — |
| Q4 25 | $0.48 | — | ||
| Q3 25 | $0.84 | $1.33 | ||
| Q2 25 | $0.34 | — | ||
| Q1 25 | $0.07 | — | ||
| Q4 24 | $0.36 | — | ||
| Q3 24 | $0.27 | $-0.60 | ||
| Q2 24 | $0.52 | $-0.68 | ||
| Q1 24 | $0.71 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $1.1B |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | — | ||
| Q3 25 | $285.9M | $786.9M | ||
| Q2 25 | $222.2M | — | ||
| Q1 25 | $197.8M | — | ||
| Q4 24 | $162.8M | — | ||
| Q3 24 | $120.0M | $920.0M | ||
| Q2 24 | $271.6M | $701.7M | ||
| Q1 24 | $318.0M | $698.8M |
| Q4 25 | $301.7M | — | ||
| Q3 25 | $274.8M | $1.1B | ||
| Q2 25 | $232.2M | — | ||
| Q1 25 | $234.4M | — | ||
| Q4 24 | $228.8M | — | ||
| Q3 24 | $234.3M | $1.2B | ||
| Q2 24 | $216.6M | $931.7M | ||
| Q1 24 | $222.2M | $935.3M |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.1B | $973.7M | ||
| Q1 24 | $1.1B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $142.2M |
| Free Cash FlowOCF − Capex | $122.4M | $142.2M |
| FCF MarginFCF / Revenue | 59.6% | 68.4% |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 7.25× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | — | ||
| Q3 25 | $78.4M | $142.2M | ||
| Q2 25 | $72.4M | — | ||
| Q1 25 | $55.4M | — | ||
| Q4 24 | $84.6M | — | ||
| Q3 24 | $-9.0M | $-49.2M | ||
| Q2 24 | $67.4M | $-32.9M | ||
| Q1 24 | $61.9M | $-43.8M |
| Q4 25 | $122.4M | — | ||
| Q3 25 | $78.3M | $142.2M | ||
| Q2 25 | $72.4M | — | ||
| Q1 25 | $54.6M | — | ||
| Q4 24 | $84.1M | — | ||
| Q3 24 | $-9.2M | $-49.7M | ||
| Q2 24 | $67.1M | $-33.9M | ||
| Q1 24 | $61.4M | $-45.1M |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 37.4% | 68.4% | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 46.2% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 42.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | 1.19× | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
